Colorectal cancer and molecular targeted agents: progress--with caveats
Tenner, L.L.; O'Neil, B.H.
Oncology 28(2): 125; 128
2014
ISSN/ISBN: 0890-9091 PMID: 24701699 Document Number: 675788
Document emailed within 1 workday
Related Documents
Kato, S. 2013: New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(1): 6-9Grothey, A. 2006: Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer Oncology 20(14 Suppl 10: 21-28
Furuta, M.; Yokota, T. 2018: The Combination of Molecular Targeted Agents with Radiotherapy in Head and Neck Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(3): 419-423
Chen, Z.Y.; Wang, X.; Wu, T.; Liu, Y.C.; Wang, P.Y. 2017: Progress of molecular subtypes of colorectal cancer Zhonghua Zhong Liu Za Zhi 39(9): 641-645
Naito, Y.; Doi, T. 2013: Novel molecular-targeted agents for GIST(Regorafenib etc.) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(1): 15-18
Hwang, J.; Marshall, J.L. 2006: Targeted therapy for colorectal cancer Current Opinion in Investigational Drugs 7(12): 1062-1066
Rajpal, S.; Venook, A.P. 2006: Targeted therapy in colorectal cancer Clinical Advances in Hematology and Oncology: H&o 4(2): 124-132
Sablin, M.-P.; Dreyer, C.; Colichi, C.él.; Bouattour, M.; Faivre, S. 2010: Targeted therapies in colorectal cancer La Revue du Praticien 60(8): 1094-1099
Oikonomou, E.; Pintzas, A. 2006: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies Anticancer Research 26(2a): 1077-1084
Tongyoo, A. 2010: Targeted therapy: novel agents against cancer Journal of the Medical Association of Thailand 93(Suppl 7): S311-S323
Mano, H. 2009: New molecular targeted EML4-ALK for lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(8): 1268-1270
Nonomura, N.; Nakayama, M.; Takayama, H.; Nishimura, K.; Okuyama, A. 2008: Molecular-targeted therapy for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 54(1): 63-66
Wcisło, G. 2008: Molecular underpinnings of the targeted therapy for cancer Acta Poloniae Pharmaceutica 65(6): 633-640
Hashimoto, Y.; Naruyama, H.; Ando, R.; Okada, S.; Tozawa, K.; Kohri, K. 2008: Molecular targeted therapy for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 54(1): 57-61
Jacob, A.; Mathew, A. 2016: Optimal use of Bone-Targeted Agents in Breast Cancer Oncology 30(8): 703-704
Lea, P.; Ling, M. 2008: New molecular assays for cancer diagnosis and targeted therapy Current Opinion in Molecular Therapeutics 10(3): 251-259
Deshpande, H.A.; Gettinger, S.N.; Sosa, J.A. 2010: Targeted therapy for thyroid cancer: An updated review of investigational agents Current Opinion in Investigational Drugs 11(6): 661-668
Li, Z.; Jin, K.; Lan, H.; Teng, L. 2011: Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? Hepato-Gastroenterology 58(106): 411-416
Tahara, M. 2008: Recent advances in molecular-targeted drugs in head and neck cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(5): 745-752
Okano, M.; Ohtake, T.; Saji, S. 2016: Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- their Potential in the Future Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(4): 398-403